Cefaclor-induced hypersensitivity: Differences in the incidence of anaphylaxis relative to other 2nd and 3rd generation cephalosporins

Cefaclor, a second-generation oral cephalosporin, is the most frequently prescribed cephalosporin in Korea. Studies, however, have yet to analyze the incidence of cefaclor-associated adverse drug reactions (ADRs), including hypersensitivity (HS), according to total national usage rates. This study a...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2021-07, Vol.16 (7), p.e0254898-e0254898
Main Authors: Rhyou, Hyo-In, Nam, Young-Hee, Kim, Su-Chin, Doo, Go-Eun, Ha, Chae-Yeon, Nam, Hee-Joo, Woo, Sung-Dae, Lee, Youngsoo, Jang, Jae-Hyuk, Lee, Hyun-Young, Ye, Young-Min
Format: Article
Language:English
Subjects:
Adverse events
Anaphylaxis
Annual reports
Antibiotics
Biology and Life Sciences
Cefaclor
Cephalosporins
Classification
Clinical trials
Demographics
Demography
Drug dosages
Health insurance
Health risks
Hospitals
Hypersensitivity
Immunology
Insurance
Internal medicine
Medicine
Medicine and Health Sciences
Prescriptions
Side effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cefaclor, a second-generation oral cephalosporin, is the most frequently prescribed cephalosporin in Korea. Studies, however, have yet to analyze the incidence of cefaclor-associated adverse drug reactions (ADRs), including hypersensitivity (HS), according to total national usage rates. This study aimed to investigate the incidence rates and clinical features of cefaclor ADRs reported to the Korean Adverse Event Reporting System (KAERS) and Health Insurance Review and Assessment Service (HIRA) database for the most recent 5 years. Reviewing the HIRA database, which contains information on all insurance claims, including prescribed medications and patient demographics, we identified the total number of individuals who had been prescribed cefaclor and other cephalosporins including 2 nd generation without cefaclor and 3 rd generation antibiotics from January 2014 to December 2018. Additionally, we retrospectively analyzed all ADRs reported to the KAERS for these drugs over the same study period. Incidence rates for ADRs, HS, and anaphylaxis to cefaclor were 1.92/10,000 persons, 1.17/10,000 persons, and 0.38/10,000 persons, respectively, lower than those to other 2 nd and 3 rd cephalosporins. Among all ADRs, HS (60.9% vs. 43.6% vs. 44.8%, P
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0254898